CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 155 enrolled
Drug / intervention
HP802-247 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01737762
NCT01737762Phase 3Completed

A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

Healthpoint·interventional·Posted Nov 30, 2012·Updated Jul 26, 2017

In Brief

A Phase 3 clinical trial evaluating HP802-247 and Vehicle for Venous Leg Ulcers. Completed, enrolled 155 participants across 43 sites in 3 countries.

Detailed Summary

This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA). At least 250 subjects will participate. The study is going to be conducted in approximately 50 sites in the United States and Canada.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Puerto Rico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 30, 2012
Enrollment StartNov 1, 2012
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 13.6 years ago

Interventions

HP802-247biological

HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.

Vehiclebiological